Publikace se zaměřuje na dějiny Biologického ústavu Lékařské fakulty Masarykovy univerzity v Brně. Určeno odborné veřejnosti.

• Keywords
• Brno (Česko),
• MeSH
• Academies and Institutes history   MeSH
• Biology history   MeSH
• Biomedical Research history   MeSH
• History, 20th Century MeSH
• History, 21st Century MeSH
• Medicine MeSH
• Universities history   MeSH
• Education history   MeSH
• Check Tag
• History, 20th Century MeSH
• History, 21st Century MeSH
• Publication type
• Monograph MeSH
• Geographicals
• Czech Republic MeSH
• Czechoslovakia MeSH

• Conspectus
• Lékařské vědy. Lékařství
• NML Fields
• dějiny lékařství
• pedagogika
• věda a výzkum

• About
• Masarykova univerzita. Biologický ústav Authority

Sarcomas are a heterogeneous group of mesenchymal tumours, with a great variability in their clinical behaviour. While our knowledge of sarcoma initiation has advanced rapidly in recent years, relatively little is known about mechanisms of sarcoma progression. JUN-murine fibrosarcoma progression series consists of four sarcoma cell lines, JUN-1, JUN-2, JUN-2fos-3, and JUN-3. JUN-1 and -2 were established from a single tumour initiated in a H2K/v-jun transgenic mouse, JUN-3 originates from a different tumour in the same animal, and JUN-2fos-3 results from a targeted in vitro transformation of the JUN-2 cell line. The JUN-1, -2, and -3 cell lines represent a linear progression from the least transformed JUN-2 to the most transformed JUN-3, with regard to all the transformation characteristics studied, while the JUN-2fos-3 cell line exhibits a unique transformation mode, with little deregulation of cell growth and proliferation, but pronounced motility and invasiveness. The invasive sarcoma sublines JUN-2fos-3 and JUN-3 show complex metabolic profiles, with activation of both mitochondrial oxidative phosphorylation and glycolysis and a significant increase in spared respiratory capacity. The specific transcriptomic profile of invasive sublines features very complex biological relationships across the identified genes and proteins, with accentuated autocrine control of motility and angiogenesis. Pharmacologic inhibition of one of the autocrine motility factors identified, Ccl8, significantly diminished both motility and invasiveness of the highly transformed fibrosarcoma cell. This progression series could be greatly valuable for deciphering crucial aspects of sarcoma progression and defining new prognostic markers and potential therapeutic targets.

• Publication type
• Journal Article MeSH

• MeSH
• Congresses as Topic MeSH
• Education, Medical, Graduate * MeSH

• Publication type
• Meeting Abstract MeSH

• MeSH
• Financing, Construction MeSH
• Hospitals, Teaching economics   organization & administration   MeSH
• Hospitals, University economics   organization & administration   legislation & jurisprudence   MeSH
• Physician Executives MeSH
• Hospital Administration MeSH
• Publication type
• Newspaper Article MeSH

• Keywords
• kinematografie,
• MeSH
• Science * history   instrumentation   MeSH
• Investigative Techniques MeSH
• Publication type
• Historical Article MeSH

• About
• Purkyně, Jan Evangelista, 1787-1869 Authority

This project is intent on assesment of molecular biology markers useful in prediction of therapeutic response in ovarian cancer patients by:1)Determination of ABCB1, ABCC1, GST polymorphisms, resistance proteins Pgp, MRP1, in vitro drug resistance/sensitivity and evaluation of their correlation with medical outcome (PFS, OS, side effects). 2) Assay of polymorphisms of the Interleukin-8 gene, endoglin, FGF, angiopoetin gene expression, pro-angiogenesis markers (VEGF,TGF?,TGFß,bFGF) and their correlation with kind of primary farmacotherapy and medical outcome (PFS, OS).3) Analysis of cardiotoxicity of standard primary chemotherapy (Paclitaxel + Carboplatin) versus primary therapy (Paclitaxel + Carboplatin + Bevacizumab) by ECG, blood pressure, ECHO, markers of cardiotoxicity (NT-proBNP,cTnT,cTnI,CKMB,MYO,h-FABP,GPBB) and their correlation with genetic polymophisms and drug resistance. This project support molecular biology prediction of the therapeutic response in ovarian cancer patients.

Projekt řeší molekulární biologii ovariálních karcinomů ve vztahu k odpovědi na léčbu. 1)Zhodnocení genových polymorfismů ABCB1,ABCC1,GST, proteinů Pgp, MRP1-kódovaných těmito geny, chemorezistence/chemosensitivity in vitro (MTT test) u pacientek diagnostikovaných 2013-2015 a retrospektivně u pacientek s již stanoveným Pgp, MRP1, MTT testem 2006-2009 ve vztahu k PFS a OS. 2) Stanovení genových polymorfismů interleukinu 8, genové exprese endoglinu,FGF,angiopoetinu a proangiogenních faktorů(VEGF,TGF?,TGFß,bFGF) v závislosti na odpovědi a typu primární léčby u pacientek diagnostikovaných 2013-2015 a retrospektivně z ovariální nádorové tkáně zamražené 2006-2009. 3) Zhodnocení kardiotoxicity paklitaxel+karboplatina versus paklitaxel+karboplatina+bevacizumab (EKG,TK,ECHOsrdce,markery kardiotoxicity NTproBNP,cTnT,cTnI,CKMB,MYO,hFABP,GPBB) a její vztah k chemorezistenci a genovým polymorfismům. Projekt umožní molekulárně biologickou predikci odpovědi na léčbu u pacientek s karcinomem ovaria.

• MeSH
• ATP-Binding Cassette Transporters analysis   MeSH
• Survival Analysis MeSH
• Bevacizumab adverse effects   MeSH
• Drug Resistance, Neoplasm MeSH
• Cytotoxicity Tests, Immunologic MeSH
• Echocardiography MeSH
• Enzyme-Linked Immunosorbent Assay methods   utilization   MeSH
• Fibroblast Growth Factor 2 analysis   MeSH
• Glutathione S-Transferase pi analysis   MeSH
• Calgranulin B analysis   MeSH
• Carboplatin adverse effects   MeSH
• Carcinoma drug therapy   MeSH
• Cardiotoxicity MeSH
• Molecular Biology MeSH
• Biomarkers, Tumor MeSH
• Ovarian Neoplasms drug therapy   MeSH
• Drug-Related Side Effects and Adverse Reactions MeSH
• ATP Binding Cassette Transporter, Subfamily B analysis   MeSH
• Paclitaxel adverse effects   MeSH
• Polymerase Chain Reaction methods   utilization   MeSH
• Polymorphism, Genetic MeSH
• Multidrug Resistance-Associated Proteins analysis   MeSH
• Antineoplastic Combined Chemotherapy Protocols MeSH
• Receptors, Vascular Endothelial Growth Factor analysis   MeSH
• Transforming Growth Factor alpha analysis   MeSH
• Transforming Growth Factor beta analysis   MeSH
• Treatment Outcome MeSH
• Women MeSH

• Conspectus
• Patologie. Klinická medicína
• NML Fields
• gynekologie a porodnictví
• onkologie
• biologie
• genetika, lékařská genetika
• NML Publication type
• závěrečné zprávy o řešení grantu IGA MZ ČR

• Publication type
• Meeting Abstract MeSH

• MeSH
• Philosophy MeSH
• Universities MeSH
• Publication type
• Personal Narrative MeSH